A dynamic and versatile pharmaceutical company with regional horizons in Latin America.
Axon Pharma is an independent multinational pharmaceutical company built on high-standards science and management.
Today, Axon Pharma is one of the fastest growing companies with proven track record in CNS and OTC segments. Expanding its portfolio into numerous therapeutic areas:
Successful in-licensed Partnership based on Excellence and Open and Clear communication.
Our mission is offering innovative and best in class products to enhance health and quality of life, encouraging an environment of ethic and integrity.
Our ambition is making innovation a reality to patients and consumers.
Open and clear communication; committing to excellence; keeping high moral standards.
Axon Pharma has a regional presence in Latin America.
Axon Pharma headquarters are located in Santiago, Chile, having presence in all Latin American Markets and has own subsidiaries in Colombia, Peru and Venezuela.
Our executive and management team has a wealth of regional experience within the pharmaceutical industry. In particular, the team has depth knowledge of the Latin American Regulatory Systems and an outstanding marketing performance.
We have a proven successful track record in CNS and OTC.
Axon Pharma – Chile
Presidente Riesco 5335
Of. 302
Las Condes
Santiago, Chile
+56 2 2964 9430
Treatment of psychosomatic manifestations of anxiety.
Active: Etifoxine (as Etifoxine hydrochloride).
Pharmacotherapeutic group: Other anxiolytics.
Therapeutic indications:
Stresam is indicated in adults for the treatment of psychosomatic manifestations of anxiety (in accordance to DSM-IV).
How Supplied:
Package containing 60 capsules contained in heat-formed blister packs consisting of aluminium foil and polyvinyl chloride.
Hyperkinetic motor disorders with Huntington's chorea.
Active: Tetrabenazine
Pharmacotherapeutic group: other nervous system drugs.
The central effects of Tetmodis closely resemble those of Reserpine, but it differs from the latter in having less peripheral activity and being much shorter acting. Tetrabenazine inhibits the re-uptake of monoamines in synaptic nerve terminals by a reversible and short-term binding to the vesicular monoamine transporter (VMAT) especially in peripheral and central neurons,with higher affinity for VMAT2 than for VMAT1.
Therapeutic indications:
Tetmodis is indicated for hyperkinetic motor disorders with Huntington’s chorea.
How Supplied:
White round high-density polyethylene (HDPE) tablet container with a child-resistant, tamper-evident polypropylene (PP) screw cap with mounted desiccant containing 112 tablets.
Schizophrenia - Manic episode - Bipolar disorder.
Active: Quetiapine (as Quetiapine hemifumarato).
Pharmacotherapeutic group: Antipsychotic.
Therapeutic indications:
GOFYL tablet is indicated for the treatment of:
How Supplied:
Schizophrenia - Manic episode - Bipolar disorder.
Active: Olanzapine
Pharmacotherapeutic group: Psycholeptics, diazepines, oxazepines, thiazepines and oxepines.
Therapeutic indications:
OLANZYL is indicated for:
How Supplied:
Schizophrenia - Manic episodes - Alzheimer's dementia.
Active: Risperidone
Pharmacotherapeutic group: Other antipsychotics.
Therapeutic indications:
How Supplied:
Nityr tablets 10 mg
Active ingredient: Nitisinone
Therapeutic indications:Treatment of patients with Hereditary Tyrosinemia Type 1 (HT-1) in combination with a dietary restriction of tyrosine and phenylalanine
Presentation:Box with a HDPE bottle containing 60 tablets of Nityr tablets 10 mg.
Active Ingredients: Methylphenidate
Therapeutic indications:
Treatment of Attention – Deficit / Hyperactivity disorder within a comprehensive program that includes psychological, educational and social measures. Narcolepsy treatment.
Presentation:
Active Ingredients: Carbamazepine
Therapeutic indications:
Epilepsia:
Presentation:
Active Ingredients: Oxcarbazepine
Therapeutic indications:
Indicated as monotherapy or as an attached therapy in the treatment of partial seizures in adults with epilepsy and as joint therapy in the treatment of partial seizures in children aged 4 to 16 years with epilepsy Trileptal is indicated for the treatment of partial epileptic seizures (which includes subtypes of simple, complex, and partial seizures that progress to generalized secondary seizures) and of generalized tonic-clonic seizures in adults and children at least 1 month of age.
Presentation:
Active Ingredients:Each coated tablet contains: Levodopa; Carbidopa; Entacapone.
Therapeutic indications:
It´s indicated for the treatment of patients with Parkinson’s disease and the fluctuations of the final measures not stabilized with the treatment with levodopa / dopa decarboxylase inhibitor (ddc).
Presentation:
Acute diarrhea - Antibiotic associated diarrhea - Traveler´s diarrhea.
Active: Saccharomyces boulardii CNCM I-745.
Pharmacotherapeutic group: Antidiarrheal microorganisms.
Therapeutic indications:
Perenteryl is indicated for the symptomatic treatment of acute nonspecific diarrhoea and in the prevention and symptomatic treatment of diarrheal diseases caused by antibiotics.
How Supplied:
Acute diarrhea - Antibiotic associated diarrhea - Traveler´s diarrhea.
Active: Saccharomyces boulardii CNCM I-745.
Pharmacotherapeutic group: Antidiarrheal microorganisms.
Therapeutic indications:
Perenteryl is indicated for the symptomatic treatment of acute nonspecific diarrhoea and in the prevention and symptomatic treatment of diarrheal diseases caused by antibiotics.
How Supplied:
Anti-snoring solution.
Action: Anti-snore.
Ingredients: Polysorbate 80, Glycerol 85%, Sodium Chloride.
Intended use:
ASONOR is indicated for reducing or completely removing strong snoring with the aim to reduce the prevalence of OSA, obstructive sleep apnoea.
How Supplied:
Package containing 1 transparent 30 ml HDPE container with upside/down delivery pump system with nasal adapter for jet-stream with 30 ml of solution.
Pain in Acute Otitis Media - Pain in Barotrauma.
Active Ingredients: Phenazone 4.00 g; lidocaine hydrochloride 1.00 g.
Pharmacotherapeutic group: Local Analgesic/ Antiinflamatory for otological use.
Therapeutic indications:
Local symptomatic treatment of certain painful conditions of the middle ear with intact tympanic membrane: Congestive acute otitis media, so-called phlyctenular viral otitis, barotrauma otitis.
How Supplied:
OTIPAX is supplied in container Type III amber glass with lid 15 ml high density polyethylene (OV2) with security seal.
Bifidobacterium longum unique culture 35624
Presentation:
Bifidobacterium lactis BL-04, Lactobacillus rhamnosus GG, Vitamin C and Vitamin D
Probiotics plus vitamins
Presentation:
Pack of 30 tablets
Pack of 30 individual sticks
Entresto:
Active Ingredient: Sacubitril/Valsartan.
Pharmacotherapeutic group: ARNI (Angiotensin II Receptor blocker Neprilysin Inhibitor)
Therapeutic indications:
ENTRESTO is indicated for:
Reducing the risk of cardiovascular death and hospitalization due to heart failure in patients with chronic heart failure (NYHA class II-IV) and reduced ejection fraction. Entresto is usually given in conjunction with other heart failure therapies, instead of an ACE inhibitor or other angiotensin receptor blocker.
Presentation:
Each film-coated tablet contains 24.3 mg sacubitril and 25.7 mg valsartan (as sacubitril, valsartan and sodium salt complex).
Each film-coated tablet contains 48.6 mg sacubitril and 51.4 mg valsartan (as sacubitril, valsartand and sodium salt complex).
Each film-coated tablet contains 97.2 mg sacubitril and 102.8 mg valsartan (as sacubitril, valsartan and sodium salt complex).
Antihypertensive.
Active ingredient: Valsartan.
Pharmacotherapeutic group: Antagonist of angiotensin II.
Therapeutic indications:
Arterial hypertension
Treatment of hypertension.
Heart failure
Treatment of heart failure (NYHA classes II-IV) in adults receiving regular treatments with diuretics, digitalis and either angiotensin converting enzyme (ACE) inhibitors or beta-blockers, but not both; it is not mandatory that the patient be receiving all of these regular treatments.
Patients after a myocardial infarction
Post myocardial infarction
TAREG is indicated for the reduction of mortality in clinically stable patients with signs, symptoms or radiologic findings suggesting left ventricular failure or systolic dysfunction of the left ventricle
Presentation:
Antihypertensive.
Active ingredient: Valsartan with Hydrochlorothiazide
Pharmacotherapeutic group:
Combination of an antagonist of angiotensin II (valsartan) with a diuretic (hydrochlorothiazide).
Therapeutic indications:
Treatment of (arterial) hypertension in adults over 18 years.
Tareg D is indicated for the treatment of hypertension when monotherapy has failed to achieve a satisfactory control of arterial tension.
Presentation:
Coated tablets of 80/12.5 mg, 160/12.5 mg, 160/25 mg, 320/12.5 mg and 320/25 mg.
Antihypertensive.
Active ingredient: Valsartan and Amlodipine
Pharmacotherapeutic group:
Association of an antagonist of angiotensin II (valsartan) and a dihydropyridine derivative (amlodipine)
Therapeutic indications:
Indicated for patients whose arterial presure is not adequately controlled with monotherapy of amlodipine or valsartan.
Treatment for essential hypertension. It may be used in patients whose arterial pressure is not adequaltelly controlled with monotherapy. It may also be used as initial therapy in patients who probably need several drugs for an adequate control of their arterial pressure.
Presentation:
Antihypertensive.
Active ingredients: Valsartan with Amlodipine and Hydrochlorothiazide
Pharmacotherapeutic group:
Association of an antagonist of angiotensin II (valsartan) with a dihydropyridin derivative (amlodipine) and a thiazide diuretic (hydrochlorothiazide).
Therapeutic indications:
Treatment of (arterial) idiopatic hypertension.
This association in fixed doses is not indicated for the initial treatment of hypertension
Presentation:
Hypoglycemic agent
Active ingredient: Vildagliptin/Vildagliptin+metformin.
Pharmacotherapeutic group: Oral antidiabetic – Dipeptidyl-peptidase-4 inhibitor
Therapeutic indications:
Galvus is indicated:
As an adjunct to diet and exercise to improve glycemic control in
patients with monotherapy for Type 2 diabetes mellitus. It may be associated with metformin, sulfonylureas or thiazolidinediones.
Galvus/Met is indicated:
For the treatment of Type 2 diabetes mellitus in patientswhose glycemia is not
adequately controlled by the maximum tolerated dose of metformin as monotherapy administered orally, or patients already being treated with the combination of vildagliptin and metformin in individual tablets.
Presentation:
Hypoglycemic agent
Active ingredient: Vildagliptin/Vildagliptin+metformin.
Pharmacotherapeutic group: Oral antidiabetic – Dipeptidyl-peptidase-4 inhibitor
Therapeutic indications:
Galvus is indicated:
As an adjunct to diet and exercise to improve glycemic control in
patients with monotherapy for Type 2 diabetes mellitus. It may be associated with metformin, sulfonylureas or thiazolidinediones.
Galvus is indicated:
For the treatment of Type 2 diabetes mellitus in patientswhose glycemia is not
adequately controlled by the maximum tolerated dose of metformin as monotherapy administered orally, or patients already being treated with the combination of vildagliptin and metformin in individual tablets.
Presentation:
In Axon Pharma we care and value long term partnership relationships, guaranteeing a solid commercial platform in Latin America to foreign pharmaceutical companies.
We strive for partners who share our value for open and clear communication, commitment to excellence and innovation in healthcare.
Our current products are from the following therapeutic areas:
Axon Pharma is constantly seeking for innovative products to improve patients and consumers quality of life.
Our people are the most valuable asset to suceed in the dynamic, competitive and expanding healthcare market. This is why in Axon Pharma we put as a priority the development of our team, assuring a great place to work. We continually seek to grow our organization through the recruitment of people who are talented, creative and motivated.
In Axon Pharma we believe that loving what we do is the only way to do a great work, and the only way to be satisfied with it.
Want to work with us?
upload your CV
